Toxicology – Venlafaxine and Related SNRIs

Core Concept

The historical term “bicyclic antidepressants” is no longer a useful modern toxicology classification for venlafaxine.

Venlafaxine is now classified as a serotonin–norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, is also marketed as an antidepressant.

Venlafaxine overdose is clinically important because substantial poisoning can cause:

• Seizures
• Serotonin toxicity
• Tachycardia and hypertension
• CNS depression
• QRS or QT abnormalities
• Ventricular dysrhythmias
• Hypotension and cardiogenic shock in severe cases

The older description of venlafaxine overdose as predominantly “mild CNS depression” substantially understates its potential severity.

There is no specific antidote.

Historical Drugs

Older literature grouped several structurally related drugs together.

Venlafaxine

Remains widely used and is the principal clinically relevant drug in this older chapter.

Viloxazine

The source describes viloxazine as investigational. This is outdated.

Viloxazine has subsequently been used clinically in some jurisdictions, including as a nonstimulant treatment for ADHD. Its modern pharmacology and overdose profile should not simply be assumed to be identical to venlafaxine.

Zimelidine

Withdrawn decades ago after association with serious neurologic adverse effects, including Guillain–Barré syndrome. It is primarily of historical interest.

Mechanism of Venlafaxine

Venlafaxine inhibits reuptake of:

• Serotonin (5-HT)
• Norepinephrine (NE)

This increases synaptic monoamine concentrations.

At lower therapeutic exposure, serotonergic effects predominate; noradrenergic effects become more prominent as exposure increases.

It has relatively little direct muscarinic, histamine, or α₁-antagonist activity compared with classic TCAs.

Metabolism

Venlafaxine undergoes hepatic metabolism, importantly through CYP2D6, producing the active metabolite:

O-desmethylvenlafaxine = desvenlafaxine

Both parent drug and active metabolite contribute to clinical effects.

Renal elimination is important for the drug and its metabolites, so renal impairment can prolong exposure.

Immediate-Release vs Extended-Release

Venlafaxine is available in immediate- and extended-release formulations.

This distinction matters in overdose because modified-release products can produce:

• Delayed absorption
• Delayed peak toxicity
• Prolonged symptoms
• Delayed seizures

Therefore, a patient who initially appears well may not necessarily remain asymptomatic after a substantial extended-release ingestion.

Toxic Dose

There is no single reliable dose threshold that predicts an individual’s course.

In general:

Increasing exposure → increasing risk of seizures and cardiovascular toxicity

Very large overdoses can cause severe or fatal poisoning.

The historical statement that death had not been reported is obsolete.

Modern experience confirms that venlafaxine overdose can be fatal, particularly after massive ingestion or severe cardiovascular toxicity.

Neurologic Toxicity

Possible manifestations include:

• Dizziness
• Tremor
• Agitation
• Confusion
• Somnolence
• Myoclonus
• Seizures
• Coma

Seizures are one of the hallmark complications of significant venlafaxine overdose.

They may occur after an initially relatively benign period.

Seizures

Venlafaxine lowers the seizure threshold.

Seizures may be:

• Generalized
• Recurrent
• Delayed, especially with modified-release formulations

Complications include:

• Hypoxemia
• Aspiration
• Lactic acidosis
• Hyperthermia
• Rhabdomyolysis
• Acute kidney injury

Seizure Management

Benzodiazepines are first-line treatment for toxicant-induced seizures.

Persistent seizures may require:

• Additional benzodiazepines
• Phenobarbital
• Appropriate anesthetic therapy for refractory status epilepticus

Phenytoin is generally not preferred for toxicologic seizures.

Serotonin Toxicity

Venlafaxine can produce serotonin syndrome, particularly after substantial overdose or combination with other serotonergic drugs.

Important findings include:

• Agitation
• Diaphoresis
• Tremor
• Hyperreflexia
• Inducible or spontaneous clonus
• Ocular clonus
• Increased bowel activity
• Hyperthermia in severe cases

Severe toxicity may cause:

• Marked hyperthermia
• Rhabdomyolysis
• Coagulopathy
• Metabolic acidosis
• Multiorgan failure

Important Drug Interactions

Serotonin toxicity risk increases with other serotonergic agents, including:

• MAO inhibitors
• SSRIs
• Other SNRIs
• Certain serotonergic analgesics
• Some other serotonergic medications

Combination with an MAO inhibitor is particularly hazardous.

Sedative coingestants may increase CNS and respiratory depression.

Cardiovascular Effects

Mild or moderate poisoning commonly produces:

• Sinus tachycardia
• Mild hypertension

Increasing toxicity may produce:

• Hypotension
• QRS prolongation
• QT prolongation
• Ventricular dysrhythmias
• Myocardial dysfunction

Massive poisoning can produce profound cardiovascular collapse.

Severe Cardiovascular Toxicity

In very large overdose, venlafaxine may produce:

• Reduced myocardial contractility
• Cardiogenic shock
• Ventricular dysrhythmias
• Severe hypotension

This is clinically distinct from the usually mild cardiovascular effects of many SSRI overdoses.

ECG

An ECG is important after significant venlafaxine overdose.

Assess:

• Heart rate
• Rhythm
• QRS duration
• QT/QTc
• Conduction abnormalities

Continuous cardiac monitoring is appropriate for symptomatic or substantial poisoning.

QRS Widening

Marked QRS widening after venlafaxine overdose suggests clinically significant myocardial conduction toxicity.

Sodium bicarbonate has been used when substantial sodium-channel-like conduction toxicity is present, particularly with:

• Significant QRS widening
• Ventricular dysrhythmia associated with conduction slowing

However, venlafaxine cardiotoxicity can involve more than a simple TCA-like sodium-channel mechanism, so bicarbonate should not be assumed to reverse every cardiovascular manifestation.

QT Prolongation

QT prolongation may occur, particularly in severe poisoning or when additional risk factors are present.

Correct:

• Hypokalemia
• Hypomagnesemia
• Hypocalcemia when clinically significant

Avoid additional QT-prolonging medications when possible.

Torsades de pointes is managed according to standard toxicologic resuscitation principles.

Blood Pressure

Early findings may include hypertension because of increased noradrenergic activity.

Severe poisoning may instead progress to:

• Vasodilatory hypotension
• Myocardial dysfunction
• Cardiogenic shock

Thus, the blood-pressure pattern can change as toxicity becomes more severe.

Hypotension

Management includes assessment of:

• Volume status
• Cardiac function
• Rhythm
• Acid–base status
• Coingestants

Appropriate isotonic crystalloid may be used when indicated.

Persistent shock may require vasopressor support, commonly with norepinephrine, while severe myocardial dysfunction may require more advanced hemodynamic support.

Routine Trendelenburg positioning and a dopamine-first approach are outdated.

Refractory Cardiogenic Shock

Massive venlafaxine poisoning can occasionally cause profound reversible myocardial failure.

Severe refractory cases may require advanced critical-care support, including consideration of mechanical circulatory support such as VA-ECMO in appropriately selected patients.

ECMO supports circulation while the drug is metabolized; it does not function as a venlafaxine antidote.

Hyperthermia

Hyperthermia should raise concern for:

• Serotonin toxicity
• Recurrent seizures
• Severe agitation

Marked hyperthermia is an emergency because it can rapidly cause:

• Rhabdomyolysis
• Hepatic injury
• Coagulopathy
• Renal failure
• CNS injury

Management emphasizes sedation, control of muscular activity, and active cooling.

Antipyretics are not useful for serotonin-mediated hyperthermia.

Hyponatremia / SIADH

SNRIs can be associated with:

• SIADH
• Hyponatremia

This is particularly relevant during therapeutic use in susceptible patients, such as older adults or those taking other medications that promote hyponatremia.

Severe hyponatremia can itself produce:

• Confusion
• Seizures
• Coma

Therefore, electrolytes are important when neurologic findings are present.

Gastrointestinal Effects

Possible findings include:

• Nausea
• Vomiting
• Dry mouth
• Abdominal discomfort

These are generally secondary concerns compared with neurologic and cardiovascular toxicity.

Diagnosis

Diagnosis is primarily based on:

• Drug and formulation
• Amount
• Time of ingestion
• Symptoms
• ECG
• Coingestants

Serum venlafaxine concentrations are not routinely useful for emergency management.

Laboratory Evaluation

Mild uncomplicated exposure may require limited testing.

Significant poisoning may warrant:

• Electrolytes
• Sodium
• Potassium
• Bicarbonate
• Creatinine
• Glucose
• CK if seizures/hyperthermia occur
• Blood gas and lactate in severe poisoning

Severe hyperthermia or shock may additionally require:

• Liver tests
• Coagulation studies
• Serial renal assessment

Occult Coingestion

Intentional antidepressant overdose should prompt assessment for important coingestants.

Acetaminophen testing is often appropriate because clinically important early poisoning can be asymptomatic.

Salicylate testing should be based on the circumstances and clinical/acid–base findings rather than used mechanically in every case.

Imaging and Lumbar Puncture

Head CT, lumbar puncture, and cultures are not routinely required merely because venlafaxine causes altered mental status or a seizure.

They should be considered when:

• The diagnosis remains uncertain
• Focal neurologic deficits occur
• Trauma is possible
• CNS infection is suspected
• Mental status fails to follow the expected toxicologic course

Initial Management

Priorities are:

Airway/breathing → seizure control → temperature → ECG/circulation → identify serotonin toxicity → monitor for delayed deterioration

Supportive care remains the foundation of treatment.

Physostigmine

Physostigmine has no routine role in venlafaxine poisoning.

Venlafaxine does not produce a classic pure antimuscarinic syndrome, and significant poisoning carries seizure and cardiovascular risks.

GI Decontamination

Do not induce vomiting.

Routine gastric lavage is obsolete.

A single dose of activated charcoal may be considered after a substantial recent ingestion when:

• The airway is reliably protected
• Aspiration risk is acceptable
• Expected benefit justifies treatment

It should never delay stabilization of seizures, hyperthermia, or cardiovascular toxicity.

Extended-Release Ingestion

Because extended-release venlafaxine can remain within the GI tract for prolonged periods, substantial ingestion may require longer monitoring than an immediate-release exposure.

Selected very large modified-release ingestions may warrant specialist discussion regarding additional GI decontamination strategies, but these are not routine measures for every overdose.

Hemodialysis and Hemoperfusion

Conventional hemodialysis and hemoperfusion do not provide useful routine venlafaxine elimination because of its pharmacokinetic characteristics.

Dialysis may still be required for a separate indication such as severe renal failure, but it should not be viewed as the primary antidotal treatment.

Monitoring

Significant poisoning requires monitoring of:

• Mental status
• Respiratory function
• Heart rate
• Blood pressure
• ECG
• Core temperature
• Seizure activity

Severe cases additionally require monitoring of:

• CK
• Electrolytes
• Renal function
• Lactate/acid–base status
• Liver function
• Coagulation

Observation

The older assumption that toxicity simply appears within a few hours and resolves within 24–48 hours is too rigid.

Observation should consider:

• Immediate- vs extended-release preparation
• Estimated exposure
• Symptoms
• ECG
• Seizures
• Serotonin toxicity
• Coingestants
• Clinical trajectory

Delayed seizures are particularly important after extended-release venlafaxine.

Admission

Hospital admission is appropriate for:

• Seizure
• Persistent altered mental status
• Serotonin toxicity
• Hyperthermia
• Significant QRS or QT abnormality
• Dysrhythmia
• Persistent hypotension
• Evidence of myocardial dysfunction
• Significant metabolic or end-organ injury

Severe cardiovascular toxicity, recurrent seizures, or marked hyperthermia warrants intensive care.

Pregnancy

The historical FDA pregnancy letter category is obsolete.

Management of significant overdose during pregnancy prioritizes maternal:

• Airway
• Oxygenation
• Blood pressure
• Temperature
• Seizure control

Severe maternal hypoxemia, shock, hyperthermia, or seizures also threaten fetal well-being.

Safeguarding

The historical rigid age thresholds for neglect or intentional poisoning are inappropriate.

Pediatric exposures should instead be evaluated according to:

• Developmental capability
• Medication accessibility
• Circumstances
• Consistency of history
• Recurrent unexplained exposures
• Broader safeguarding concerns

Intentional self-poisoning requires appropriate safety assessment after medical stabilization.

Prognosis

Most mild venlafaxine overdoses recover with supportive treatment.

Increasingly severe poisoning carries risk of:

• Recurrent seizures
• Serotonin toxicity
• Hyperthermia
• Rhabdomyolysis
• Ventricular dysrhythmias
• Cardiogenic shock
• Multiorgan injury

Massive venlafaxine overdose can be fatal, contrary to the historical source.

Important Modernization of the Older Source

• “Bicyclic antidepressant” is an outdated classification for venlafaxine; it is an SNRI.
• Desvenlafaxine is its pharmacologically active metabolite and also a marketed drug.
• Venlafaxine overdose is not simply a mild CNS-depressant syndrome.
• Seizures are a major hallmark of significant poisoning.
• Extended-release preparations can cause delayed seizures and prolonged toxicity.
• Serotonin syndrome is an important complication, especially with serotonergic coexposure.
• Massive overdose can cause QRS/QT abnormalities, ventricular dysrhythmias, myocardial dysfunction, cardiogenic shock, and death.
• Zimelidine is historical; viloxazine should not simply be treated as interchangeable with venlafaxine.
• Phenytoin is generally not preferred for toxicologic seizures.
• Trendelenburg and routine dopamine-first shock treatment are outdated.
• Severe reversible cardiogenic shock may occasionally require advanced mechanical circulatory support.
• Routine gastric lavage is obsolete.
• Activated charcoal has a selective role when the airway is safe.
• Hemodialysis does not meaningfully enhance venlafaxine elimination.
• Observation should account for formulation and delayed toxicity rather than follow a fixed short period.
• There is no specific antidote.

Key Points

• Venlafaxine = SNRI, not a clinically useful “bicyclic” category.
• Major overdose risks = seizures + serotonin toxicity + cardiovascular toxicity.
• Mild poisoning often causes tachycardia, hypertension, tremor, and CNS symptoms.
• Severe poisoning can progress to hyperthermia, QRS/QT abnormalities, dysrhythmias, hypotension, and cardiogenic shock.
• Extended-release venlafaxine can produce delayed toxicity.
• Benzodiazepines are first-line for seizures.
• Significant hyperthermia requires control of muscular activity and active cooling.
• Obtain ECG monitoring after substantial or symptomatic overdose.
• Dialysis is not useful for routine toxin removal.
• No specific antidote exists.